Prevention of venous thromboembolism

Seminars in Thrombosis and Hemostasis

Volumn 32, Issue 8, 2006, Pages 755-766

  Pini, Mario ^a   Spyropoulos, Alex C ^b  

^a Ospedale di Fidenza   (Italy)

^b LOVELACE MEDICAL CENTER   (United States)

Author keywords

Prevention of venous thromboembolism; Prophylaxis of venous thromboembolism; Thromboprophylaxis; Thrombotic risk assessment

Indexed keywords

ANTIVITAMIN K; BEMIPARIN; CERTOPARIN; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; IVOR; LOW MOLECULAR WEIGHT HEPARIN; MONOEMBOLEX; NADROPARIN; PARNAPARIN; REVIPARIN; TINZAPARIN;

BLEEDING; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; MOBILIZATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; THROMBOSIS; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; POLYSACCHARIDES; STOCKINGS, COMPRESSION; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 33845620364     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-955458     Document Type: Review

References (109)

1. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:3385-4005
2. Gallus AS, Hirsh J, O'Brien SE, McBride JA, Turtle RJ, Gent M. Prevention of venous thromboembolism with small subcutaneous doses of heparin. JAMA 1976;235:1980-1982
3. Kakkar W, Corrigan TP, Fossard DP. Prevention of fatal postoperative pulmonary embolism by low dose of heparin. An international multicentre trial. Lancet 1975;2:45-51
4. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-1335
5. Pini M, Froehlich J, Bergmann JF, et al. Comparison of US and European practices in the prevention of venous thromboembolism in hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE). Blood 2003;11:320(Abst)
6. Hirsh J. Low molecular weight heparin. Thromb Haemost 1993;70:204-207
7. Petitou M, Lormeau JC, Choay J. Chemical synthesis of glycosaminoglycans: new appoach to antithrombotic drugs. Nature 1991;350(suppl):30-33
8. Eriksson BI, Bauer KA, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001;345:1298-1304
9. Bauer KA, Eriksson BI, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001;345:1305-1310
10. Lassen MR, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002;359:1715-1720
11. Turpie AG, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism in elective hip replacement surgery: a randomised double blind trial. Lancet 2002;359:1721-1726
12. Mismetti P, LaPorte S, Zufferey P, Epinat M, Decousus H, Cucherat M. Prevention of venous thromboembolism in orthopedic surgery with vitamin K antagonists: a meta-analysis. J Thromb Haemost 2004;2:1058-1070
13. Wells PS, Lensing AWA, Hirsh J. Graduated compression stockings in the prevention of postoperative venous thromboembolism. Arch Intern Med 1994;154:67-72
14. Amarigiri SV, Lees TA. Elastic compression stockings for prevention of deep vein thrombosis. Cochrane Database Syst Rev 2000;1: CD001484
15. Borly L, Wille-Jørgensen P, Rasmussen MS. Systematic review of thromboprophylaxis in colorectal surgery-an update. Colorectal Dis 2005;7:122-127
16. Muhe E. Intermittent sequential high-pressure compression of the leg: a new method of preventing deep vein thrombosis. Am J Surg 1984;147:781-785
17. Hull RD, Raskob GE, Gent M, et al. Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip replacement. JAMA 1990;263:2313-2317
18. Turpie AG, Hirsh J, Gent M, Julian D, Johnson J. Prevention of deep vein thrombosis in potential neurosurgical patients: a randomised trial comparing graduated compression stockings alone or graduated compression stockings plus intermittent pneumatic compression with control. Arch Intern Med 1989;149:679-681
19. Vaughn BK, Knezevich S, Lombardi AV Jr, Mallory TH. Use of the Greenfield filter to prevent fatal embolism associated with total hip and knee arthroplasty. J Bone Joint Surg (Am) 1989;71:1542-1548
20. Nicolaides AN, Bergqvist D, Hull R, et al. Prevention of venous thromboembolic events: International Consensus Statement (guidelines according to scientific evidence). Int Angiol 1997;16:3-38
21. Ageno W. Applying risk assessment models in general surgery: overview of our clinical experience. Blood Coagul Fibrinolysis 1999;10(suppl):S71-S78
22. Bergqvist D, Lindblad B, Matzsch T. Risk of combining low molecular weight heparin for thromboprophylaxis and epidural or spinal anesthesia. Semin Thromb Hemost 1993;19(suppl):147-151
23. Wysowski DK, Talarico L, Bacsanyi J, Botstein P. Spinal and epidural haematoma and low molecular weight heparin. N Engl J Med 1998;338:1774-1775
24. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988;318:1162-1173
25. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients: results of meta-analysis. Ann Surg 1988;208:227-240
26. Mismetti P, Laporte S, Darmon JY, Buchmuller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001;88:913-930
27. Nurmohamed MT, Rosendaal FR, Büller HR, et al. Low molecular weight heparin versus standard heparin in general and orthopedic surgery: a meta-analysis. Lancet 1992;340:152-156
28. Leizorovicz A, Haugh MC, Chapuis FR, Samama MM, Boissel JP. Low molecular weight heparins in the prevention of post-operative thrombosis. BMJ 1992;305:913-920
29. Kakkar VV, Murray WJ. Efficacy and safety of low-molecular-weight heparin (CY216) in preventing post-operative venous thrombo-embolism: a co-operative study. Br J Surg 1985;98:266a
30. The European Fraxiparin Study Group. Comparison of a low molecular weight and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. Br J Surg 1988;75:1058-1063
31. Koch A, Bouges S, Ziegler S, Dinkel H, Daures JP, Victor N. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical interventions: update of previous meta-analyses. Br J Surg 1997;84:750-759
32. Bergqvist D, Burmark US, Flordal PA, et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients. Br J Surg 1995;82:496-501
33. Kakkar VV, Cohen A, Edmonson RA, et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group. Lancet 1993;341:259-264
34. Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002;346:975-980
35. Wille-Jørgensen P. Low dosage heparin combined with either dihydroergotamine or graduated supportive stockings. Combined prevention of thrombosis in colonic surgery. Ugeskr Laeger 1986;148:501-503
36. Wille-Jørgensen P, Hauch O, Dimo B, Christensen SW, Jensen R, Hansen B. Prophylaxis of deep venous thrombosis after acute abdominal operations. Surg Gynecol Obstet 1991;172:44-48
37. Agnelli G, Bergqvist D, Cohen A, et al. Randomized double-blind study to compare the efficacy and safety of postoperative fondaparinux (Arixtra) and preoperative dalteparin in the prevention of venous thromboembolism after high-risk abdominal surgery: the Pegasus Study. Blood 2003;102:13a
38. Riber C, Alstrup N, Nymann T, Bogstad JW, Wille-Jørgensen P, Tonnesen H. Postoperative thromboembolism after day-case herniorrhaphy. Br J Surg 1996;83:420-421
39. Baca I, Schneider B, Kohler T, Misselwitz F, Zehle A, Muhe F. Prevention of venous thromboembolism in patients undergoing minimally invasive interventions and brief inpatient treatment: Results of a multicenter, prospective, randomized, controlled study with a low-molecular-weight heparin. Chirurgia (Bucur) 1997;68:1275-1280
40. Bounameaux H, Didier D, Polat O, Desmarais S, de Moerloose P, Huber O. Antithrombotic prophylaxis in patients undergoing laparoscopic cholecystectomy. Thromb Res 1997;86:271-273
41. White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 2003;90:446-455
42. Donat R, Mancey-Jones B. Incidence of thromboembolism after transurethral resection of the prostate (TURP): a study on TED stockings prophylaxis and literature review. Scand J Urol Nephrol 2002;36:119-123
43. Kucher N, Koo S, Quiroz R, et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med 2005;352:969-977
44. Warwick D, Williams MH, Bannister GC. Death and thromboembolic disease after total hip replacement. A series of 1162 cases with no routine chemical prophylaxis. J Bone Joint Surg Br 1995;77:6-10
45. Khaw FM, Moran CG, Pinder IM, Smith SR. The incidence of fatal pulmonary embolism after knee replacement with no prophylactic anticoagulation. J Bone Joint Surg Br 1993;75:940-941
46. Planes A, Vovhelle N, Mazas F, et al. Prevention of postoperative venous thrombosis: a randomised trial comparing unfractionated heparin and low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost 1988;60:407-410
47. Colwell CW, Spiro TE, Trowbridge AA, et al. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep vein thrombosis after elective hip replacement, A clinical trial comparing efficacy and safety. J Bone Joint Surg Am 1994;76:3-14
48. Anderson DR, O'Brien BJ, Levine MN, Roberts R, Wells PS, Hirsh J. Efficacy and cost of low molecular weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Ann Intern Med 1993;119:1105-1112
49. Leyvraz PF, Richard J, Bachmann F, et al. Adjusted versus fixed dose subcutaneous heparin in the prevention of deep vein thrombosis after total hip replacement. N Engl J Med 1983;309:954-958
50. Hull RD, Pineo GF, MacIsaac S. Low-molecular-weight heparin prophylaxis: pre-operative versus postoperative initiation in patients undergoing elective hip surgery. Thromb Res 2001;101:155-162
51. Eriksson BI, Lassen MRfor the PENTasacharide in Hip-FRActure Surgery Plus (PENTIPHRA PLUS) Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 2003;163:1337-1342
52. Lassen MR, Borris LC, Anderson BS, et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty-the Danish Prolonged Prophylaxis (DaPP) study. Thromb Res 1998;89:281-287
53. Planes A, Vochelle N, Darmon JY, Fagola M, Bellaud M, Huet Y. Risk of deep venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996;348:224-228
54. Bergqvist D, Benoni G, Björgell O, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996;335:696-700
55. Dahl OE, Andreassen G, Aspelin T, et al. Prolonged thromboprophylaxis following hip replacement surgery-results of a double-blind prospective, randomised, placebo-controlled study with dalteparin (Fragmin). Thromb Haemost 1997;77:26-31
56. Prandoni P, Bruchi O, Sabbion P, et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Arch Intern Med 2002;162:1966-1971
57. Comp PC, Spiro TE, Friedman RJ, et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am 2001;83:336-345
58. White RH, Romano PS, Zhou H, Rodrigo J, Bargar W. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998;158:1525-1531
59. Hjelmstedt A, Bergvall U. Incidence of thrombosis in patients with tibial fractures: a phlebographic study. Acta Chir Scand 1968;134:209-218
60. Abelseth G, Buckley RE, Pineo GE, Hull R, Rose MS. Incidence of deep vein thrombosis in patients with fractures of the lower extremity distal to the hip. J Orthop Trauma 1996;10:230-235
61. Stringer MD, Steadman CA, Hedges AR, Thomas EM, Morley TR, Kakkar W. Deep vein thrombosis after elective knee surgery. An incidence study in 312 patients. J Bone Joint Surg Br 1989;71:492-497
62. Kujath P, Spannagel U, Habscheid W. Incidence and prophylaxis of deep venous thrombosis in outpatients with injury of the lower limb. Haemostasis 1993;23(suppl 1):20-26
63. Kock HJ, Schmit-Neuerburg KP, Hanke J, Rudofsky G, Hirche H. Thromboprophylaxis with low-molecular-weight heparin in outpatients with plaster-cast immobilization of the leg. Lancet 1995;346:459-461
64. Lassen MR, Borris LC, Nakov RL. Use of the low-molecular-weight heparin reviparin to prevent deep vein thrombosis after leg injury requiring immobilization. N Engl J Med 2002;347:726-730
65. Jørgensen PS, Warming T, Hansen K, et al. Low molecular weight heparin (Innohep) as thromboprophylaxis in out-patients with a plaster cast: a venographic controlled study. Thromb Res 2002;105:477-480
66. Giannadakis K, Gehling H, Sitter H, Acherbach S, Hahne H, Gotzen L. Is a general pharmacological thromboembolism prophylaxis necessary in ambulatory treatment by plaster cast immobilization in lower limb injuries? Unfallchirurg 2000;103:475-478
67. Solis G, Saxby T. Incidence of DVT following surgery of the foot and ankle. Foot Ankle Int 2002;23:411-414
68. Demers C, Marcoux S, Ginsberg JS, Laroche F, Cloutier R, Poulin J. Incidence of venographically proved deep vein thrombosis after knee arthroscopy. Arch Intern Med 1998;158:47-50
69. Schippinger G, Wirnsberger GH, Obernosterer A, Babinski K. Thromboembolic complications after arthroscopic knee surgery. Incidence and risk factors in 111 patients. Acta Orthop Scand 1998;69:144-146
70. Jaureguito JW, Greenwald AE, Wilcox JF, Paulos LE, Rosenberg TD. The incidence of deep venous thrombosis after arthroscopic knee surgery. Am J Sports Med 1999;27:707-710
71. Wirth T, Schneider B, Misselwitz F, et al. Prevention of venous thromboembolism after knee arthroscopy with low-molecular-weight heparin (reviparin): results of a randomised controlled trial. Arthroscopy 2001;17:393-399
72. Michot M, Conen D, Holtz D, et al. Prevention of deep-vein thrombosis in ambulatory arthroscopic knee surgery: a randomised trial of prophylaxis with low-molecular-weight heparin. Arthroscopy 2002;18:257-263
73. Belch JJ, Lowe GD, Pollock JG, Forbes CD, Prentice CR. Low dose heparin in the prevention of deep-vein thrombosis after aortic bifurcation graft surgery. Thromb Haemost 1980;42:1429-1433
74. Olin JW, Graor RA, O'Hara P, Young JR. The incidence of deep venous thrombosis in patients undergoing abdominal aortic aneurysm resection. J Vasc Surg 1993;18(6):1037-1041
75. Hollyoak M, Woodruff P, Muller M, Daunt N, Weir P. Deep venous thrombosis in postoperative vascular surgical patients: a frequent finding without prophylaxis. J Vasc Surg 2001;34(4):656-660
76. Saarinen J, Sisto T, Laurikka J, Salenius JP, Tarkka M. Late sequelae of acute deep venous thrombosis: evaluation five and ten years after. Phlebology 1995;10:106-109
77. Farkas JC, Chapuis C, Combe S, et al. A randomised controlled trial of a low-molecular-weight heparin (Enoxaparin) to prevent deep-vein thrombosis in patients undergoing vascular surgery. Eur J Vasc Surg 1993;7(5):554-560
78. Kudsk KA, Fabian TC, Baum S, Gold RE, Mangiante E, Voeller G. Silent deep vein thrombosis in immobilized multiple trauma patients. Am J Surg 1989;158(6):515-519
79. Meissner MH, Chandler WL, Elliott JS. Venous thromboembolism in trauma: a local manifestation of systemic hypercoagulability? J Trauma 2003;54(2):224-231
80. Geerts WH, Jay RM, Code KI, et al. A comparison of low-dose heparin with low molecular weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 1996;335:701-707
81. Elliott CG, Dudney TM, Egger M, et al. Calf-thigh sequential pneumatic compression compared with plantar venous pneumatic compression to prevent deep-vein thrombosis after non-lower extremity trauma. J Trauma 1999;47(1):25-32
82. Consortium for Spinal Cord Medicine. Prevention of thromboembolism in spinal cord injury. J Spinal Cord Med 1997;20(3):259-283
83. Cade JF. High risk of the critically ill for venous thromboembolism. Crit Care Med 1982;10(7):448-450
84. Belch JJ, Lowe GDO, Ward AG, Forbes CD, Prentice CRM. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 1981;26:115-117
85. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999;341(11):793-800
86. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004;110(7):874-879
87. Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of Fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. Br Med J 2006;332:325-329
88. Nicolaides AN, Breddin HK, Fareed J, et al. Prevention of venous thromboembolism. International Consensus Statement. Int Angiol 2001;20(1):1-37
89. Levine M, Rickles FR. Treatment of venous thromboembolism in cancer patients. Haemostasis 1998;28(suppl 3):66-70
90. Alikhan R, Cohen AT, Combe S, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med 2004;164(9):963-968
91. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients. Arch Intern Med 2000;160:3415-3420
92. Cohen AT, Edmondson RA, Phillips MJ, Ward VP, Kakkar W. The changing pattern of venous thromboembolic disease. Haemostasis 1996;26:65-71
93. Baglin TP, White K, Charles A. Fatal pulmonary embolism in hospitalised medical patients. J Clin Pathol 1997;50:609-610
94. Goldhaber SZ, Tapson VF. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol 2004;93(2):259-262
95. Tapson VF, Decousus H, Piovella F, Zotz RB, Allegrone J, Anderson FA. A multinational observational cohort study in acutely ill medical patients of practices in prevention of venous thromboembolism: findings of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE). Blood 2003;11:321a
96. Halkin H, Goldberg J, Modan M, Modan B. Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis. Ann Intern Med 1982;96:561-565
97. Gardlund B. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet 1996;347:1357-1361
98. Lechler E, Schramm W, Flosbach CW. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low molecular weight heparin (enoxaparin). Haemostasis 1996;26(suppl 2):49-56
99. Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 2003;145:614-621
100. Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated heparin or low-molecular-weight heparins: a meta-analysis of randomized clinical trials. Thromb Haemost 2000;83:14-19
101. Alikhan R. A safety analysis of thromboprophylaxis in acute medical illness. Thromb Haemost 2003;89:590-591
102. Lloyd AC, Anderson PM, Quinlan DJ, Bearne A. Economic evaluation of the use of enoxaparin for thromboprophylaxis in acutely ill medical patients. Journal of Medical Economics 2001;4:99-113
103. McGarry LJ, Thompson D, Weinstein MC, Goldhaber SZ. Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients. Am J Manag Care 2004;10(9):632-642
104. Turpie AGG, Levine MN, Hirsh J, et al. Double-blind randomised trial of Org 10172 low molecular weight heparinoid in prevention of deep vein thrombosis in thrombotic stroke. Lancet 1987;1(8532):523-526
105. Turpie AGG. Orgaran in the prevention of deep vein thrombosis in stroke patients. Haemostasis 1992;22:92-98
106. Hillbom M, Erilä T, Sotaniemi K, Tatlisumak T, Sarna S, Kaste M. Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double-blind study. Acta Neurol Scand 2002;106:84-92
107. Muir KW, Watt A, Baxter G, Grosset DG, Lees KR. Randomized trial of graded compression stockings for prevention of deep-vein thrombosis after acute stroke. QIM 2000;93(6):359-364
108. Kapoor M, Kupfer YY, Tessler S. Subcutaneous heparin prophylaxis significantly reduces the incidence of venous thromboemolic events in the critically ill. Crit Care Med 1999;27(12 suppl):A69
109. Goldhaber SZ, Kett DH, Cusumano CJ, et al. Low molecular weight heparin versus minidose unfractionated heparin for prophylaxis against venous thromboembolism in medical intensive care unit patients: a randomized controlled trial. JACC 2000;35(suppl):325A